



News Release

December 17, 2019

Unichem Pharmaceuticals Launches Generic Buspar® – Buspirone

Unichem Pharmaceuticals (USA), Inc. is pleased to announce the launch of Buspirone Tablets, the latest addition to our growing portfolio.

Buspirone is the generic version of Buspar® from Bristol-Myers Squibb. Buspirone is used to treat anxiety. It helps to relieve symptoms such as fear, tension, irritability, dizziness, and other physical symptoms such as pounding heartbeat. IQVIA recorded sales of \$107.5M and 1.2B tablets of Buspirone during the last 12 months ending October 2019. Buspirone is available in 5mg & 10mg – 100ct & 500ct bottles, 15mg – 60ct, 100ct, 180ct & 500ct bottles, 30mg – 60ct & 500ct bottles.

Unichem’s Chief Financial Officer, Rajaram Pai, had the following to say regarding the launch of Buspirone: “Buspirone provides another example of Unichem’s focus on service, innovation, and reliability to our growing portfolio of cost beneficial products to help better serve our patients.”

About Unichem Pharmaceuticals (USA), Inc:

Unichem Pharmaceuticals (USA), Inc. is a wholly owned subsidiary of Unichem Laboratories Limited (NSE: UNICHEMLAB). Unichem Pharmaceuticals has a growing list of US FDA approved products and a strong product pipeline to support our growth plans. Unichem Pharmaceutical’s focus is on providing quality and cost-effective products with reliable and efficient customer service.

Any interest in buying products please contact the below National Accounts Representatives.

Contact: Mary Rotunno

Contact: Neal Miller

Contact: Kaitlin Alexander

Phone: (201) 621-3710

Phone: (303) 886-1260

Phone: (201) 519-0802

Email: mrotunno@unichemusa.com

Email: nmiller@unichemusa.com

Email: kalexander@unichemusa.com

Disclaimer:

Estimates, expectations, and business plans in this release are forward-looking statements. Actual future results, including and without limitation, target dates, project plans, capacity costs, and other statements relating to any future business plans, may differ from our expectations. The information contained in this press release is accurate only as of the date each press release was originally issued. The matters discussed herein may also be affected by risks and uncertainties described from time to time within the Pharmaceutical industry. The company assumes no obligation to update any future occurrence and will not be held accountable for any use of this information.